Literature DB >> 6642960

Alleviation of chemotherapy induced emesis by oral lorazepam and domperidone.

P Warde, B Cantwell, J Fennelly, W Powderly, R Conroy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6642960     DOI: 10.1007/BF02954731

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  8 in total

1.  Oral lorazepam to improve tolerance of cytotoxic therapy.

Authors:  M Friedlander; J H Kearsley; M H Tattersall
Journal:  Lancet       Date:  1981-06-13       Impact factor: 79.321

2.  Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting.

Authors:  I L Swann; E N Thompson; K Qureshi
Journal:  Br Med J       Date:  1979-11-10

3.  Emesis as a critical problem in chemotherapy.

Authors:  J Laszlo; V S Lucas
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

4.  Compatibility of high doses of both oral domperidone and neuroleptics in chronic psychotics.

Authors:  R Deberdt
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

5.  Lorazepam, a new benzodiazepine derivative, in the treatment of anxiety: a double-blind clinical evaluation.

Authors:  L McCurdy
Journal:  Am J Psychiatry       Date:  1979-02       Impact factor: 18.112

6.  High-dose dexamethasone for prevention of cis-platin-induced vomiting.

Authors:  M S Aapro; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Domperidone as an antiemetic in paediatric oncology.

Authors:  A O'Meara; M G Mott
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.